HIGHLIGHTS
- who: Short report et al. from the of Cambridge, Cambridge, UK have published the article: Feasibility of combined screening for upper gastrointestinal adenocarcinoma risk by serology and Cytosponge testing: the SUGAR study, in the Journal: (JOURNAL)
- what: TFF3 has also been reported to be a promising serum marker for preneoplastic changes of the stomach.12 13 This study aims to assess the feasibility of combined serological assessment of PG1, PG2, G17, TFF3 and anti-H. pylori antibodies in a cohort that has been tested with the Cytosponge to identify additional patients who might benefit from . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.